Skip to main content

Table 6 PP Analysis for RVGE and AGE Hospitalizations and ED Visits Stratified by Intensity of Surveillance

From: Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

Type of Health Care Encounter

Type of Site

Hospitalizations and ED visits

Hospitalizations

ED visits

 

RV5 # (rate)a of events

Placebo # (rate)a of events

% Rate Reduction

(95% CI)

RV5 # (rate)a of events>

Placebo # (rate)a of events

% Rate Reduction

(95% CI)

RV5 # (rate)a of events

Placebo # (rate)a of events

% Rate Reduction

(95% CI)

Sites in the Efficacy Substudy

RVGE

10

(4.3)

128

(51.8)

91.0

(81.7, 95.5)

1

(0.4)

27

(10.9)

95.7

(68.5, 99.4)

9

(3.8)

101

(40.9)

89.7

(78.1, 95.1)

AGE

280

(76.2)

483

(131.4)

39.7

(28.0, 49.5)

31

(8.4)

95

(25.8)

66.1

(48.0, 77.8)

249

(67.8)

388

(105.5)

33.2

(18.9, 45.1)

Sites not in the Efficacy Substudy

RVGE

10

(0.6)

241

(15.6)

95.9

(92.2, 97.8)

5

(0.3)

117

(7.6)

95.8

(89.6, 98.3)

5

(0.3)

124

(8.0)

96.0

(90.2, 98.4)

AGE

815

(31.6)

1385

(53.8)

41.2

(35.0, 46.8)

206

(8.0)

480

(18.7)

57.1

(49.0, 64.0)

609

(23.6)

905

(35.2)

32.8

(24.2, 40.4)

  1. a The numbers in the RV5 and Placebo columns represent the number (rate) of events; the rates reflect the incidence density expressed as the annual number of events per 1000 person years